Dedee Murrell MD DSc’s Post

View profile for Dedee Murrell MD DSc, graphic

Professor & Head, Department of Dermatology, St George Hospital, University of NSW, Sydney

We eagerly await the results of this pivotal clinical trial of dupilumab I designed together with dermatology colleagues Pascal Joly, Victoria Werth and Arsalan Shabbir for bullous pemphigoid. Here is the trial rationale and design. https://lnkd.in/gs5tZbcd

  • No alternative text description for this image
Rekar Sharif

Pharmacist , Reasercher , Clinical pharmacist , Clinical pharmacology , Dermatological Pharmacology

6mo

IL4 is the main for production of desmogline antibody in bullous skin autoimmunity So dupilumab is a selective iL4 and iL13 inhibitor as a novel treatment ,,,

Like
Reply

To view or add a comment, sign in

Explore topics